Correlation between gene mutation status and selected clinical features
Overview
Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 92 genes and 7 clinical features across 40 patients, one significant finding detected with Q value < 0.25.

  • KCNN3 mutation correlated to 'Time to Death'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between mutation status of 92 genes and 7 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, one significant finding detected.

Clinical
Features
Time
to
Death
YEARS
TO
BIRTH
GENDER RADIATION
THERAPY
HISTOLOGICAL
TYPE
RACE ETHNICITY
nMutated (%) nWild-Type logrank test Wilcoxon-test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test Fisher's exact test
KCNN3 7 (18%) 33 2.19e-05
(0.0141)
0.618
(1.00)
0.681
(1.00)
0.568
(1.00)
0.763
(1.00)
0.063
(0.841)
0.652
(1.00)
MYD88 3 (8%) 37 0.0413
(0.841)
1
(1.00)
0.553
(1.00)
1
(1.00)
0.236
(0.939)
0.617
(1.00)
0.541
(1.00)
FRG1 8 (20%) 32 0.877
(1.00)
0.648
(1.00)
0.69
(1.00)
0.313
(0.954)
1
(1.00)
1
(1.00)
0.079
(0.841)
MLL2 14 (35%) 26 0.944
(1.00)
0.294
(0.939)
0.329
(0.981)
0.0705
(0.841)
0.137
(0.903)
0.299
(0.939)
0.157
(0.903)
TPPP 5 (12%) 35 0.291
(0.939)
0.854
(1.00)
1
(1.00)
0.574
(1.00)
1
(1.00)
1
(1.00)
0.298
(0.939)
CHIT1 6 (15%) 34 0.0449
(0.841)
0.155
(0.903)
0.195
(0.939)
0.564
(1.00)
1
(1.00)
0.00756
(0.841)
0.153
(0.903)
B2M 8 (20%) 32 0.207
(0.939)
0.25
(0.939)
0.114
(0.903)
0.29
(0.939)
0.0146
(0.841)
0.761
(1.00)
1
(1.00)
TPTE2 11 (28%) 29 0.689
(1.00)
0.575
(1.00)
0.295
(0.939)
0.655
(1.00)
0.157
(0.903)
0.4
(1.00)
1
(1.00)
RHPN2 6 (15%) 34 0.888
(1.00)
0.12
(0.903)
0.668
(1.00)
1
(1.00)
0.712
(1.00)
0.0434
(0.841)
0.648
(1.00)
FOXD4L1 7 (18%) 33 0.431
(1.00)
0.569
(1.00)
0.681
(1.00)
1
(1.00)
1
(1.00)
0.144
(0.903)
0.652
(1.00)
DND1 4 (10%) 36 0.377
(0.993)
0.191
(0.939)
0.638
(1.00)
1
(1.00)
1
(1.00)
0.199
(0.939)
0.297
(0.939)
ATXN1 7 (18%) 33 0.757
(1.00)
0.165
(0.906)
0.681
(1.00)
1
(1.00)
1
(1.00)
0.257
(0.939)
0.652
(1.00)
TP53 6 (15%) 34 0.291
(0.939)
0.519
(1.00)
0.0645
(0.841)
1
(1.00)
0.276
(0.939)
0.719
(1.00)
0.341
(0.988)
CDC27 10 (25%) 30 0.618
(1.00)
0.341
(0.988)
0.711
(1.00)
0.607
(1.00)
1
(1.00)
0.0519
(0.841)
0.693
(1.00)
EPB41L4A 4 (10%) 36 0.378
(0.993)
0.169
(0.906)
0.638
(1.00)
0.502
(1.00)
0.553
(1.00)
1
(1.00)
1
(1.00)
NOTCH2NL 4 (10%) 36 0.607
(1.00)
0.787
(1.00)
0.638
(1.00)
0.502
(1.00)
0.315
(0.954)
0.0233
(0.841)
0.57
(1.00)
KRT3 4 (10%) 36 0.0511
(0.841)
0.857
(1.00)
0.136
(0.903)
1
(1.00)
1
(1.00)
0.0916
(0.875)
1
(1.00)
OR1S2 10 (25%) 30 0.624
(1.00)
0.803
(1.00)
0.482
(1.00)
1
(1.00)
0.618
(1.00)
0.286
(0.939)
0.231
(0.939)
RGPD5 5 (12%) 35 0.00451
(0.841)
0.26
(0.939)
1
(1.00)
1
(1.00)
0.639
(1.00)
0.12
(0.903)
0.627
(1.00)
TNFAIP3 6 (15%) 34 0.183
(0.937)
0.256
(0.939)
0.668
(1.00)
1
(1.00)
0.15
(0.903)
0.117
(0.903)
0.648
(1.00)
RBMXL1 4 (10%) 36 0.363
(0.993)
0.207
(0.939)
1
(1.00)
0.104
(0.903)
0.55
(1.00)
1
(1.00)
0.57
(1.00)
CCDC66 4 (10%) 36 0.0896
(0.875)
0.636
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.0924
(0.875)
0.297
(0.939)
NOTCH2 7 (18%) 33 0.807
(1.00)
0.206
(0.939)
1
(1.00)
0.568
(1.00)
0.531
(1.00)
0.518
(1.00)
0.652
(1.00)
PCMTD1 6 (15%) 34 0.996
(1.00)
0.88
(1.00)
0.373
(0.993)
1
(1.00)
0.278
(0.939)
0.216
(0.939)
1
(1.00)
FAM120B 5 (12%) 35 0.302
(0.939)
0.743
(1.00)
1
(1.00)
0.574
(1.00)
1
(1.00)
0.266
(0.939)
0.298
(0.939)
SMARCA2 4 (10%) 36 0.392
(1.00)
0.332
(0.981)
0.136
(0.903)
1
(1.00)
1
(1.00)
1
(1.00)
0.297
(0.939)
C11ORF40 4 (10%) 36 0.567
(1.00)
0.543
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.00934
(0.841)
0.297
(0.939)
ZSCAN5A 3 (8%) 37 0.345
(0.988)
0.98
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
KRTAP4-5 4 (10%) 36 0.752
(1.00)
0.3
(0.939)
0.638
(1.00)
1
(1.00)
0.314
(0.954)
0.0233
(0.841)
0.297
(0.939)
DEFA1 4 (10%) 36 0.119
(0.903)
0.62
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.135
(0.903)
0.297
(0.939)
SIRPA 5 (12%) 35 0.173
(0.908)
0.357
(0.992)
0.373
(0.993)
0.574
(1.00)
0.203
(0.939)
0.17
(0.906)
1
(1.00)
TMPRSS13 3 (8%) 37 0.57
(1.00)
0.504
(1.00)
0.553
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.541
(1.00)
CYP2A6 4 (10%) 36 0.377
(0.993)
0.0202
(0.841)
0.283
(0.939)
0.502
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
AR 7 (18%) 33 0.615
(1.00)
0.0841
(0.86)
0.681
(1.00)
1
(1.00)
0.204
(0.939)
0.0987
(0.903)
1
(1.00)
ARHGEF5 3 (8%) 37 0.653
(1.00)
0.607
(1.00)
0.262
(0.939)
1
(1.00)
1
(1.00)
0.0366
(0.841)
0.541
(1.00)
RNF39 3 (8%) 37 0.653
(1.00)
0.292
(0.939)
0.553
(1.00)
1
(1.00)
0.235
(0.939)
0.0358
(0.841)
1
(1.00)
ABCA1 5 (12%) 35 0.315
(0.954)
0.5
(1.00)
0.373
(0.993)
0.574
(1.00)
1
(1.00)
0.169
(0.906)
0.298
(0.939)
CS 3 (8%) 37 0.653
(1.00)
0.218
(0.939)
0.262
(0.939)
0.403
(1.00)
0.447
(1.00)
0.0362
(0.841)
1
(1.00)
IFITM3 4 (10%) 36 0.731
(1.00)
0.367
(0.993)
0.638
(1.00)
1
(1.00)
0.555
(1.00)
0.00875
(0.841)
0.297
(0.939)
RANBP2 5 (12%) 35 0.105
(0.903)
0.0751
(0.841)
0.0712
(0.841)
1
(1.00)
0.639
(1.00)
0.12
(0.903)
0.627
(1.00)
KLHL6 6 (15%) 34 0.284
(0.939)
0.471
(1.00)
0.373
(0.993)
0.564
(1.00)
1
(1.00)
0.478
(1.00)
0.153
(0.903)
ZNF814 10 (25%) 30 0.865
(1.00)
0.348
(0.99)
0.711
(1.00)
0.163
(0.906)
0.376
(0.993)
0.354
(0.99)
0.133
(0.903)
CYP4A11 4 (10%) 36 0.11
(0.903)
0.0748
(0.841)
0.283
(0.939)
1
(1.00)
1
(1.00)
0.00832
(0.841)
0.297
(0.939)
PIM1 8 (20%) 32 0.905
(1.00)
0.447
(1.00)
0.229
(0.939)
1
(1.00)
0.117
(0.903)
0.543
(1.00)
0.677
(1.00)
POTEE 7 (18%) 33 0.868
(1.00)
0.345
(0.988)
1
(1.00)
0.568
(1.00)
1
(1.00)
0.256
(0.939)
0.081
(0.841)
OR52E6 3 (8%) 37 0.0778
(0.841)
0.0424
(0.841)
0.553
(1.00)
1
(1.00)
1
(1.00)
0.0761
(0.841)
0.541
(1.00)
NBPF10 8 (20%) 32 0.589
(1.00)
0.787
(1.00)
0.229
(0.939)
1
(1.00)
0.118
(0.903)
1
(1.00)
1
(1.00)
PRB2 8 (20%) 32 0.292
(0.939)
0.735
(1.00)
0.439
(1.00)
0.583
(1.00)
0.172
(0.906)
0.121
(0.903)
0.211
(0.939)
MUC6 21 (52%) 19 0.9
(1.00)
0.481
(1.00)
0.755
(1.00)
1
(1.00)
0.484
(1.00)
0.201
(0.939)
0.494
(1.00)
SALL1 5 (12%) 35 0.149
(0.903)
0.39
(1.00)
1
(1.00)
1
(1.00)
0.642
(1.00)
0.17
(0.906)
1
(1.00)
PAK2 7 (18%) 33 0.848
(1.00)
0.285
(0.939)
0.0295
(0.841)
1
(1.00)
0.126
(0.903)
0.146
(0.903)
1
(1.00)
FLG 17 (42%) 23 0.625
(1.00)
0.691
(1.00)
0.747
(1.00)
0.679
(1.00)
0.319
(0.959)
0.0804
(0.841)
0.505
(1.00)
MUC17 12 (30%) 28 0.382
(0.997)
0.275
(0.939)
0.49
(1.00)
0.151
(0.903)
0.538
(1.00)
0.331
(0.981)
0.725
(1.00)
OR2T4 8 (20%) 32 0.388
(1.00)
0.946
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.291
(0.939)
1
(1.00)
AMAC1L3 5 (12%) 35 0.76
(1.00)
0.595
(1.00)
1
(1.00)
0.574
(1.00)
1
(1.00)
0.0533
(0.841)
0.298
(0.939)
APOB 3 (8%) 37 0.752
(1.00)
0.0181
(0.841)
1
(1.00)
0.403
(1.00)
0.45
(1.00)
0.0367
(0.841)
1
(1.00)
KRTAP4-7 8 (20%) 32 0.302
(0.939)
0.0317
(0.841)
1
(1.00)
1
(1.00)
0.259
(0.939)
0.0103
(0.841)
0.396
(1.00)
MUC16 12 (30%) 28 0.0603
(0.841)
0.4
(1.00)
0.49
(1.00)
0.645
(1.00)
0.434
(1.00)
0.0345
(0.841)
0.0674
(0.841)
NEFH 6 (15%) 34 0.335
(0.981)
0.343
(0.988)
1
(1.00)
0.564
(1.00)
0.714
(1.00)
0.478
(1.00)
0.153
(0.903)
RNASEH2B 3 (8%) 37 0.462
(1.00)
0.898
(1.00)
0.0567
(0.841)
0.403
(1.00)
1
(1.00)
0.617
(1.00)
1
(1.00)
OTOP1 4 (10%) 36 0.0243
(0.841)
0.528
(1.00)
0.638
(1.00)
1
(1.00)
1
(1.00)
0.0571
(0.841)
0.297
(0.939)
AATK 3 (8%) 37 0.0454
(0.841)
0.59
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.0764
(0.841)
0.541
(1.00)
ARID1A 5 (12%) 35 0.976
(1.00)
0.5
(1.00)
0.0712
(0.841)
0.574
(1.00)
1
(1.00)
0.014
(0.841)
0.298
(0.939)
GUCA1C 3 (8%) 37 0.0778
(0.841)
0.0424
(0.841)
0.553
(1.00)
1
(1.00)
1
(1.00)
0.0743
(0.841)
0.541
(1.00)
TRIM48 8 (20%) 32 0.061
(0.841)
0.577
(1.00)
0.69
(1.00)
0.583
(1.00)
1
(1.00)
0.226
(0.939)
1
(1.00)
CSGALNACT2 5 (12%) 35 0.256
(0.939)
0.141
(0.903)
0.631
(1.00)
0.574
(1.00)
0.639
(1.00)
0.0517
(0.841)
0.298
(0.939)
CRIPAK 6 (15%) 34 0.878
(1.00)
0.353
(0.99)
1
(1.00)
0.564
(1.00)
1
(1.00)
0.0726
(0.841)
0.153
(0.903)
DHRS4 4 (10%) 36 0.0896
(0.875)
0.636
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.0912
(0.875)
0.297
(0.939)
FAM21A 4 (10%) 36 0.163
(0.906)
0.155
(0.903)
1
(1.00)
1
(1.00)
1
(1.00)
0.136
(0.903)
0.297
(0.939)
KIAA1529 4 (10%) 36 0.844
(1.00)
0.241
(0.939)
1
(1.00)
1
(1.00)
1
(1.00)
0.134
(0.903)
0.297
(0.939)
OR2M5 4 (10%) 36 0.434
(1.00)
0.735
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.297
(0.939)
KRT6A 4 (10%) 36 0.459
(1.00)
0.183
(0.937)
0.638
(1.00)
1
(1.00)
1
(1.00)
0.0567
(0.841)
0.297
(0.939)
CYP2F1 4 (10%) 36 0.639
(1.00)
0.131
(0.903)
0.638
(1.00)
1
(1.00)
1
(1.00)
0.134
(0.903)
0.297
(0.939)
FCGBP 5 (12%) 35 0.315
(0.954)
0.177
(0.919)
0.373
(0.993)
0.574
(1.00)
1
(1.00)
0.169
(0.906)
0.298
(0.939)
ZNF493 4 (10%) 36 0.915
(1.00)
0.804
(1.00)
1
(1.00)
0.502
(1.00)
1
(1.00)
0.0234
(0.841)
1
(1.00)
HLA-B 6 (15%) 34 0.998
(1.00)
0.191
(0.939)
0.668
(1.00)
1
(1.00)
0.153
(0.903)
0.217
(0.939)
0.648
(1.00)
FCRLA 3 (8%) 37 0.752
(1.00)
0.355
(0.99)
1
(1.00)
1
(1.00)
1
(1.00)
0.0362
(0.841)
0.541
(1.00)
KLRC2 5 (12%) 35 0.334
(0.981)
0.539
(1.00)
1
(1.00)
0.574
(1.00)
1
(1.00)
0.429
(1.00)
0.298
(0.939)
CD79B 5 (12%) 35 0.403
(1.00)
0.197
(0.939)
0.373
(0.993)
0.574
(1.00)
0.055
(0.841)
0.69
(1.00)
0.627
(1.00)
TMSB4X 5 (12%) 35 0.718
(1.00)
0.513
(1.00)
0.631
(1.00)
0.161
(0.906)
0.105
(0.903)
0.69
(1.00)
0.627
(1.00)
PRB1 5 (12%) 35 0.277
(0.939)
0.623
(1.00)
1
(1.00)
1
(1.00)
0.637
(1.00)
0.121
(0.903)
0.627
(1.00)
PCDHA7 4 (10%) 36 0.455
(1.00)
0.12
(0.903)
1
(1.00)
1
(1.00)
0.314
(0.954)
1
(1.00)
1
(1.00)
OR5H14 3 (8%) 37 0.413
(1.00)
0.382
(0.997)
0.262
(0.939)
0.403
(1.00)
0.448
(1.00)
0.616
(1.00)
1
(1.00)
PER3 4 (10%) 36 0.812
(1.00)
0.839
(1.00)
0.638
(1.00)
0.502
(1.00)
0.552
(1.00)
0.133
(0.903)
1
(1.00)
PABPC1 7 (18%) 33 0.919
(1.00)
0.327
(0.981)
0.681
(1.00)
0.568
(1.00)
0.354
(0.99)
0.0205
(0.841)
0.652
(1.00)
ITGA6 3 (8%) 37 0.653
(1.00)
0.13
(0.903)
1
(1.00)
1
(1.00)
1
(1.00)
0.0757
(0.841)
0.541
(1.00)
IGSF3 6 (15%) 34 0.746
(1.00)
0.609
(1.00)
1
(1.00)
1
(1.00)
0.461
(1.00)
0.715
(1.00)
0.648
(1.00)
KRTAP1-1 3 (8%) 37 0.653
(1.00)
0.0509
(0.841)
0.553
(1.00)
1
(1.00)
1
(1.00)
0.0739
(0.841)
0.541
(1.00)
C15ORF39 3 (8%) 37 0.653
(1.00)
0.292
(0.939)
0.553
(1.00)
1
(1.00)
0.233
(0.939)
0.0354
(0.841)
1
(1.00)
ZNF880 8 (20%) 32 0.541
(1.00)
0.8
(1.00)
1
(1.00)
1
(1.00)
1
(1.00)
0.226
(0.939)
0.396
(1.00)
NBPF15 4 (10%) 36 0.378
(0.993)
0.839
(1.00)
0.136
(0.903)
1
(1.00)
1
(1.00)
1
(1.00)
0.297
(0.939)
SLC22A16 3 (8%) 37 0.752
(1.00)
0.355
(0.99)
1
(1.00)
1
(1.00)
1
(1.00)
0.0378
(0.841)
0.541
(1.00)
'KCNN3 MUTATION STATUS' versus 'Time to Death'

P value = 2.19e-05 (logrank test), Q value = 0.014

Table S1.  Gene #59: 'KCNN3 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 40 6 0.0 - 128.1 (25.5)
KCNN3 MUTATED 7 4 1.9 - 31.7 (12.8)
KCNN3 WILD-TYPE 33 2 0.0 - 128.1 (27.4)

Figure S1.  Get High-res Image Gene #59: 'KCNN3 MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

Methods & Data
Input
  • Mutation data file = sample_sig_gene_table.txt from Mutsig_2CV pipeline

  • Processed Mutation data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/GDAC_Correlate_Genomic_Events_Preprocess/DLBC-TP/19899504/transformed.cor.cli.txt

  • Clinical data file = /xchip/cga/gdac-prod/tcga-gdac/jobResults/Append_Data/DLBC-TP/19775131/DLBC-TP.merged_data.txt

  • Number of patients = 40

  • Number of significantly mutated genes = 92

  • Number of selected clinical features = 7

  • Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[3] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)